Skip to main content
Vera Therapeutics, Inc. logo

Vera Therapeutics, Inc. — Investor Relations & Filings

Ticker · VERA ISIN · US92337R1014 US Professional, scientific and technical activities
Filings indexed 418 across all filing types
Latest filing 2024-06-11 Director's Dealing
Country US United States of America
Listing US VERA

About Vera Therapeutics, Inc.

https://veratx.com/

Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological and rare diseases. The company's mission is to change the standard of care and improve patients' lives. Its lead product candidate is atacicept, a novel biologic molecule being developed for the treatment of IgA nephropathy (IgAN), a progressive autoimmune kidney disease. Vera Therapeutics aims to advance its pipeline of innovative therapies to address significant unmet medical needs within immunology.

Recent filings

Filing Released Lang Actions
Director's Dealing 2024
Director's Dealing
2024-06-11 English
Director's Dealing 2024
Director's Dealing
2024-06-11 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated May 15, 2024, reporting on the results of the 2024 Annual Meeting of Stockholders of Vera Therapeutics, Inc. It includes detailed voting results for the election of directors and ratification of the independent auditor. The key content is the submission of matters to a vote of security holders, specifically the election of directors and ratification of the auditor. This matches the definition of Declaration of Voting Results & Voting Rights Announcements (DVA). The document is about the official results from shareholder votes at the Annual Meeting, not the meeting materials or the full annual report. The length is under 5,000 characters and contains substantive voting results, so it is not a mere announcement of a report but the actual voting results. Therefore, the correct classification is DVA with high confidence.
2024-05-17 English
Director's Dealing 2024
Director's Dealing
2024-05-17 English
Director's Dealing 2024
Director's Dealing
2024-05-17 English
Director's Dealing 2024
Director's Dealing
2024-05-17 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.